{"denoms":[{"counts":[{"groupId":"BG000","value":"77"}],"units":"Participants"}],"groups":[{"description":"HD Melphalan/Cyclophosphamide followed by PBPC Rescue, alpha-interferon, \\& pamidronate","id":"BG000","title":"HD Chemo Followed by PBPC Rescue"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"75"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"29","upperLimit":"66","value":"54"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"72"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"69"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Stage I (Low Tumor Mass)"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Stage II (Intermediate Tumor Mass)"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Stage III (High Tumor Mass)"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"unrecorded"}]}],"description":"Definitions are in section 4.0 \"Staging Criteria\" of the protocol: \"Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon, Pamidronate, With or Without Thalidomide, for Patients with Multiple Myeloma\"\n\nStage I is Low Tumor Mass -- Indolent Myeloma Stage II is Intermediate Tumor Mass -- Smoldering Myeloma Stage III is High Tumor Mass","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage of Multiple Myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"IgG"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"IgA"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"unrecorded"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"M protein type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"62"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"not recorded"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Anthracycline Chemotherapy","unitOfMeasure":"Participants"}]}